Skip to main content
Premium Trial:

Request an Annual Quote

10x Genomics Acquires Epinomics

NEW YORK (GenomeWeb) – 10x Genomics said on Tuesday that it has acquired Epinomics, a startup that spun out of Stanford University to commercialize technology for mapping chromatin regions across the genome.

Epinomics has been developing its technology for clinical applications, including using epigenomic signatures to predict response to immunotherapy. It has a collaboration with Stanford's Park Institute for Cancer Immunotherapy to use biomarkers and epigenomics technology to improve cancer immunotherapies.

Privately held 10x Genomics plans to integrate Epinomics' ATAC-seq epigenetic technology onto its Chromium system and plans to launch a single-cell ATAC solution by the end of the year.

"Today's acquisition gives us a strong team, IP, and technology that has been enthusiastically validated by customers," 10x Genomics CEO Serge Saxonov said in a statement. "It provides a foundation for powerful new products and positions us well to become the leader in epigenomics."

Financial terms of the acquisition were not disclosed. Epinomics is backed by venture firms including Lightspeed Venture Partners, Felicis Ventures, and Founders Fund.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.